Merck (NYSE:MRK) inks an agreement with South Korea’s Hanmi Pharmaceutical securing exclusive global rights to the latter’s efinopegdutide (formerly HM12525A), a once-weekly glucagon-like peptide-1/glucagon receptor dual agonist, for the potential treatment of nonalcoholic steatohepatitis (NASH).
Under the terms of the deal, Merck will pay Hanmi $10M upfront, up to $860M in milestones and double-digit royalties on net sales. Hanmi retains an option to commercialize the product in Korea.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.